- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.10. | Eikon reports trial data for lung cancer drug candidate EIK1001 | 1 | Investing.com | ||
| 26.10. | Eikon Therapeutics, Inc.: Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress | 1 | GlobeNewswire (USA) | ||
| 23.10. | Eikon Therapeutics, Inc.: Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress | 3 | GlobeNewswire (USA) | ||
| 23.10. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.10. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress | 2 | GlobeNewswire (USA) | ||
| 09.09. | Inhibrx, Eikon rise after insider buying | 2 | Seeking Alpha | ||
| 03.09. | Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer | 356 | GlobeNewswire (Europe) | MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 21.08. | Cantor Fitzgerald reiterates Overweight on Eikon stock | 1 | Investing.com | ||
| EIKON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald | 2 | GlobeNewswire (USA) | ||
| 13.08. | Eikon Therapeutics, Inc. GAAP EPS of -$1.63 misses by $0.03 | 1 | Seeking Alpha | ||
| 13.08. | Eikon Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates | 436 | GlobeNewswire (Europe) | Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon's oncology portfolio, including clinical... ► Artikel lesen | |
| 11.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma | 624 | GlobeNewswire (Europe) | Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee... ► Artikel lesen | |
| 10.08. | Eikon Therapeutics adds Merck chemistry head to advisory board | 3 | Investing.com | ||
| 10.08. | Merck Chemiechef verstärkt wissenschaftlichen Beirat von Eikon Therapeutics | 4 | Investing.com Deutsch | ||
| 10.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board | 501 | GlobeNewswire (Europe) | MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 03.08. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | Eikon Therapeutics doses first patient in lung cancer trial | 1 | Investing.com | ||
| 27.07. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer | 291 | GlobeNewswire (Europe) | MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to... ► Artikel lesen | |
| 20.07. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,000 | +0,33 % | PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien | DJ PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,161 | -10,35 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| CLINUVEL | 4,524 | -1,09 % | CLINUVEL PHARMACEUTICALS LIMITED: Results of Meeting | ||
| INFLARX | 1,205 | +10,65 % | InflaRx: 2027 - warum die nächsten Studien jetzt zählen | ||
| INTELLIA THERAPEUTICS | 10,200 | +1,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DEFENCE THERAPEUTICS | 0,191 | -9,29 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | +4,00 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| BIOCRYST PHARMACEUTICALS | 6,894 | +2,25 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| CARDIOL THERAPEUTICS | 0,923 | +0,98 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen | |
| GERON | 0,885 | +1,80 % | Geron auf der Stifel Healthcare Conference 2026: RYTELO gewinnt an Dynamik | ||
| IBIO | 0,688 | -1,64 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update | ||
| ARBUTUS BIOPHARMA | 3,370 | -1,75 % | Arbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7M | ||
| IMMUNITYBIO | 6,140 | +1,49 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| IMMATICS | 5,840 | +1,74 % | Immatics Announces Third Quarter 2026 Financial Results and Business Update | Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,230 | 0,00 % | Cellectar Biosciences GAAP EPS of -$0.46 beats by $0.10 |
EIKON THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,130 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EIKON THERAPEUTICS INC finden Sie auf Wallstreet Online.